American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 201-204 , August 2009

Anabolic Interventions in ESRD: Light at the End of the Tunnel?

  • Raymond M. Hakim, MD, PhD

      Affiliations

    • Fresenius Medical Care–North America, Inc, Nashville, Tennessee
    • Corresponding Author InformationAddress correspondence to Raymond M. Hakim, MD, PhD, Fresenius Medical Care, 750 Old Hickory Blvd, Ste 230, Brentwood, TN 37027
    • ,
  • T. Alp Ikizler, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, Tennessee

References 

  1. Lowrie E, Lew N. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  2. Kopple J, Zhu X, Lew N, Lowrie E. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int. 1999;56:1136–1148
  3. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int. 1996;50:343–357
  4. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–398
  5. Ikizler TA, Wingard RL, Harvell J, et al. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999;55:1945–1951
  6. Ikizler TA, Wingard RL, Sun M, et al. Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol. 1996;7:2646–2653
  7. Ikizler T, Flakoll P, Parker R, Hakim R. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994;46:830–837
  8. Ikizler TA. Nutrition, inflammation and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17:162–167
  9. Motil KJ, Matthews DE, Bier DM, et al. Whole-body leucine and lysine metabolism: Response to dietary protein intake in young men. Am J Physiol. 1981;240:E712–E721
  10. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001;12:2797–2806
  11. Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004;66:355–366
  12. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38:1251–1263
  13. Kamiji MM, Inui A. The role of ghrelin and ghrelin analogues in wasting disease. Curr Opin Clin Nutr Metab Care. 2008;11:443–451
  14. Granado M, Martin AI, Lopez-Menduina M, et al. GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. Am J Physiol Endocrinol Metab. 2008;294:E131–E141
  15. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial. Ann Intern Med. 2008;149:601–611
  16. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in human. J Clin Endocrinol Metab. 2000;85:2402–2410
  17. Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol. 2006;17:2307–2314
  18. Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009;20:613–620
  19. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007;18:2161–2171
  20. Kopple JD, Cheung AK, Sandahl Christiansen J, et al. OPPORTUNITY: A randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1741–1751
  21. Yoshimoto A, Mori K, Sugawara A, et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol. 2002;13:2748–2752
  22. Rodriguez Ayala E, Pecoits-Filho R, Heimburger O, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: A longitudinal study. Nephrol Dial Transplant. 2004;19:421–426
  23. DeBoer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile. Endocrinology. 2008;149:827–835
  24. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: A randomized, placebo-controlled trial. J Am Soc Nephrol. 2005;16:2111–2118

 Originally published online as doi: 10.1053/j.ajkd.2009.04.018 on June 26, 2009.

PII: S0272-6386(09)00718-5

doi: 10.1053/j.ajkd.2009.04.018

American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 201-204 , August 2009

Article Tools

* Image Usage & Resolution